BioCryst beats FY2025 ORLADEYO rev guidance; FY2026 outlook $625-645M; Astria acquisition on track

BIOCRYST PHARMACEUTICALS INC

2025-FY EPS reported $1.21 revenue$874,837,000

Preliminary unaudited FY2025 ORLADEYO net revenue $601M (+37% YoY), exceeding $590-600M guidance range.
Q4 2025 ORLADEYO net revenue $151M (+22% YoY; +36% comparable basis excl European revenue).
Cash, cash equivalents, restricted cash & investments at Dec 31, 2025: $338M.
FY2026 guidance: ORLADEYO rev $625-645M; total rev $635-660M; non-GAAP op ex $380-390M (excl Astria).
Expected close of Astria Therapeutics acquisition in Q1 2026; adds $70-80M non-GAAP op ex for navenibart Phase 3 and manufacturing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.